Syed A Hussain

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi request reprint Organ preservation strategies in bladder cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Edgbaston, Birmingham B15 2TA, UK
    Expert Rev Anticancer Ther 2:641-51. 2002
  2. ncbi request reprint BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 10:571-6. 2003
  3. ncbi request reprint The systemic treatment of advanced and metastatic bladder cancer
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University Hospital Birmingham, Birmingham, UK
    Lancet Oncol 4:489-97. 2003
  4. ncbi request reprint Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 11:1005-10. 2004
  5. pmc Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
    S A Hussain
    Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Br J Cancer 90:2106-11. 2004
  6. pmc A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham B15 2TT, UK
    Br J Cancer 91:844-9. 2004
  7. ncbi request reprint Molecularly targeted therapeutics for breast cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Birmingham, England
    BioDrugs 21:215-24. 2007
  8. doi request reprint Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
    Nicholas D James
    University of Birmingham, School of Cancer Sciences, Edgbaston, Birmingham B15 2TT, United Kingdom
    N Engl J Med 366:1477-88. 2012
  9. ncbi request reprint Endocrine therapy and other targeted therapies for metastatic breast cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies and The Cancer Centre, Queen Elizabeth Hospital, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Expert Rev Anticancer Ther 4:1179-95. 2004
  10. doi request reprint Biology of testicular germ cell tumors
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK
    Expert Rev Anticancer Ther 8:1659-73. 2008

Detail Information

Publications22

  1. ncbi request reprint Organ preservation strategies in bladder cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Edgbaston, Birmingham B15 2TA, UK
    Expert Rev Anticancer Ther 2:641-51. 2002
    ..The use of cytotoxic drugs such as gemcitabine and taxanes synchronous with radiation remains experimental today but may be incorporated into refined treatment protocols in coming years...
  2. ncbi request reprint BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 10:571-6. 2003
    ..This study shows that over-expression of BCL2 in patients receiving synchronous chemoradiotherapy is an independent indicator of poor survival in muscle invasive TCC of the bladder...
  3. ncbi request reprint The systemic treatment of advanced and metastatic bladder cancer
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University Hospital Birmingham, Birmingham, UK
    Lancet Oncol 4:489-97. 2003
    ..Future studies should stratify patients according to the number of risk factors they have to avoid imbalance in treatment groups and patients should be carefully selected...
  4. ncbi request reprint Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 11:1005-10. 2004
    ..94). There was a trend towards longer survival for tumour expressing CA IX strongly. This is likely to be a reflection of the significantly higher rate of strong CA IX expression in non-invasive cancers influencing these survival data...
  5. pmc Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
    S A Hussain
    Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Br J Cancer 90:2106-11. 2004
    ..A national phase III trial BC2001 (www.bc2001.org.uk) exploring the effects of synchronous chemoradiotherapy with this regimen is currently recruiting...
  6. pmc A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham B15 2TT, UK
    Br J Cancer 91:844-9. 2004
    ..The overall median survival was 16 months (range 10.1-26.6 months). G plus C every 3 weeks is active and well tolerated in an outpatient setting, even in patients receiving prior platinum-based regimens and with poor renal reserve...
  7. ncbi request reprint Molecularly targeted therapeutics for breast cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Birmingham, England
    BioDrugs 21:215-24. 2007
    ....
  8. doi request reprint Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
    Nicholas D James
    University of Birmingham, School of Cancer Sciences, Edgbaston, Birmingham B15 2TT, United Kingdom
    N Engl J Med 366:1477-88. 2012
    ..In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone...
  9. ncbi request reprint Endocrine therapy and other targeted therapies for metastatic breast cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies and The Cancer Centre, Queen Elizabeth Hospital, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Expert Rev Anticancer Ther 4:1179-95. 2004
    ..These include strategies to overcome endocrine resistance and methods to target deregulated endocrine and growth factor signaling pathways using gene and immunotherapy approaches...
  10. doi request reprint Biology of testicular germ cell tumors
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK
    Expert Rev Anticancer Ther 8:1659-73. 2008
    ..Current understanding of the role of genetic and epigenetic factors in the etiology of germ cell tumors and the biochemical mechanisms underlying chemotherapy sensitivity and resistance is discussed in detail in this review...
  11. ncbi request reprint Role of chemotherapy in breast cancer
    Syed A Hussain
    Institute for Cancer Studies, University Hospital Birmingham, Edgbaston, Birmingham, B15 2TT, UK
    Expert Rev Anticancer Ther 5:1095-110. 2005
    ..This review discusses the evidence for various chemotherapy regimens in the adjuvant and metastatic settings, and examines the current evidence for the timing of radiotherapy in the adjuvant setting...
  12. doi request reprint Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer
    Richard T Bryan
    School of Cancer Sciences, University of Birmingham, Birmingham, UK
    Proteomics Clin Appl 5:493-503. 2011
    ..There is a need for better biomarkers to both detect bladder cancer and distinguish muscle-invasive (stage T2+) from non-invasive (stage Ta/T1) disease. We assess whether MALDI-TOF-MS of the urine peptidome can achieve this...
  13. ncbi request reprint Molecular pathways in bladder cancer: part 2
    Richard T Bryan
    The Epithelial Laboratory, Division of Medical Sciences, The Queen Elizabeth Hospital, Birmingham, UK
    BJU Int 95:491-6. 2005
  14. ncbi request reprint Gene- and immunotherapy for hepatocellular carcinoma
    Daniel H Palmer
    CR UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham, B15 2TT, UK
    Expert Opin Biol Ther 5:507-23. 2005
    ..The challenge remains to design clinical trials to optimally evaluate these agents and allow feedback to the laboratory for their ongoing development...
  15. ncbi request reprint Management of muscle invasive bladder cancer--British approaches to organ conservation
    Nicholas James
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, UK
    Semin Radiat Oncol 15:19-27. 2005
    ..This article documents the concerns that linger over the efficacy and morbidity of cisplatin-based chemotherapy and describes a national trial investigating a potentially less morbid 5FU and mitomycin alternative...
  16. doi request reprint Biology of germ cell tumors
    Yuk Ting Ma
    The Cancer Centre, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    Hematol Oncol Clin North Am 25:457-71, vii. 2011
    ..A better understanding of the molecular biology of cancer may also aid in guiding the most appropriate use of existing therapies, such as conventional chemotherapy...
  17. ncbi request reprint Systemic therapies for hepatocellular carcinoma
    Daniel H Palmer
    Cancer Research UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham B15 2TA, UK
    Expert Opin Investig Drugs 13:1555-68. 2004
    ..At present there are a number of interesting therapeutic agents with potential activity in HCC. The challenge now is the design of clinical trials to optimally evaluate these agents...
  18. ncbi request reprint Molecular markers in bladder cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Biringham B15 2TT, UK
    Semin Radiat Oncol 15:3-9. 2005
    ..It is imperative to study the role of these mechanisms in prospective clinical trials in a quest to find predictive markers that can help to tailor treatments, keeping in view the molecular heterogeneity...
  19. ncbi request reprint Endocrine therapy for early breast cancer
    Syed A Hussain
    Cancer Research UK, Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK
    Expert Rev Anticancer Ther 4:877-88. 2004
    ....
  20. ncbi request reprint Molecular pathways in bladder cancer: part 1
    Richard T Bryan
    The Epithelial Laboratory, Division of Medical Sciences, The Queen Elizabeth Hospital, Birmingham, UK
    BJU Int 95:485-90. 2005
  21. doi request reprint Management of metastatic germ cell tumors
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University Hospital Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Expert Rev Anticancer Ther 8:771-84. 2008
    ..The choice of different platinum, and total dose of etoposide and bleomycin and their impact on the clinical outcome in context of various trials is discussed in detail in this review...
  22. ncbi request reprint BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients
    Brahm Vasudev
    Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Kidney Int 68:1834-9. 2005
    ..We have thus quantified the timing, risk factors, evolution of renal function, and transplant graft outcome in renal transplant recipients with BKVN from our center...